High-throughput screening identifies FDA approved drug mitiglinide as a novel pyroptosis inhibitor and therapeutic agent for osteoarthritis
Mitiglinide, identified via FDA-drug-library screening, alleviates OA progression by suppressing NLRP3 inflammasome activation and ECM degradation via activation of the Nrf2/HO-1 signaling pathway. This positions mitiglinide as a repurposed disease-modifying OA drug candidate.
Authors
- Ning Zhuo (ORCID: https://orcid.org/0000-0002-4117-589X)
- Jiangning Wang (ORCID: https://orcid.org/0000-0003-1887-9220)
- Shiying Zhao
- Youli Zhang
- Aimin Wu (ORCID: https://orcid.org/0000-0002-8582-4599)
- Shihan Lin (ORCID: https://orcid.org/0000-0001-7182-9041)
- Hanwen Zhang (ORCID: https://orcid.org/0000-0001-8490-918X)
- Xiaolei Zhang (ORCID: https://orcid.org/0000-0003-0117-7599)
- Huilin Yu
- Zongxin Zhu
- Yifei Zhou
- Tanxin Yu
Institutions
- Wenzhou Medical University (CN)
- Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University (CN)
- Beijing Shijitan Hospital (CN)
- First Affiliated Hospital Zhejiang University (CN)
Publication Details
- Journal
- Journal of Advanced Research
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1016/j.jare.2025.12.004
- Primary Topic
- Inflammasome and immune disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00